@prefix rdfs:    <http://www.w3.org/2000/01/rdf-schema#> .
@prefix foaf:    <http://xmlns.com/foaf/0.1/> .
@prefix owl:     <http://www.w3.org/2002/07/owl#> .
@prefix vocabProperty:  <http://www4.wiwiss.fu-berlin.de/drugbank/vocab/resource/property/> .
@prefix drugbank:  <http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/> .
@prefix dbpedia:  <http://dbpedia.org/ontology/> .
@prefix map:     <file:/C:/apps/drugbank/drugbank.n3#> .
@prefix rdf:     <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix trc:     <http://www.trialresultscenter.org/property/> .
<http://www.trialresultscenter.org/study2637-SPORTIF III.htm>    <trc:trial_id>2637</trc:trial_id>spc+<trc:name>SPORTIF III, 2003</trc:name>spc+<trc:registre></trc:registre>    trc:studiedTreatment "ximelagatran 36 mg twice daily";    <trc:studiedTreatmentDetail><![CDATA[]]></trc:studiedTreatmentDetail>    <trc:controlTreatment><![CDATA[warfarin standard dose (target INR 2-3)]]></trc:controlTreatment>    <trc:controlTreatmentDetail><![CDATA[]]></trc:controlTreatmentDetail>    <trc:concomittantTreatment><![CDATA[Aspirin <100mg/day allowed
Other antithrombotic drugs were prohibited.]]></trc:concomittantTreatment>    <trc:patients><![CDATA[One or more stroke risk factor in addition to AF.High risk patients with non valvular atrial fibrillation.]]></trc:patients>    <trc:exclusionCriteria><![CDATA[Mitral stenosis,Transient AF caused by reversible disorder,Stroke within the previous 30 days or TIA within 3 days,Condition associated with increased risk of bleeding,Active infective endocarditis,Current atrial myxoma or left ventricular thrombus,Admission for acute coronary syndrome or percutaeous coronary intervention within 30 days,Requirement for chronic anticoagulation treatment for disorders other than AF,planned cardioversion,Planned major surgery,treatment with platelet inhibitor drugs other than aspirin 100mg/day or less within 10 days or fibrinolytic agents within 30 days before randomisation,Regular use of NSAI drugs,Renal insuffiency,Active liver disease or persistent elevationof liver enzymes,Childbearing potential,pregnancy or lactation,Drug addiction alcohol abuse or both,Anaemia or thrombopenia]]></trc:exclusionCriteria>    <trc:inclusionCriteria><![CDATA[Age >18,Persistent or paroxysmal AF verified by at least 2 ECG,One or more stroke risk factors in addition to AF(hypertension,age>75,previous stroke TIA or systemic embolism,left ventricular dysfunction,age>65+coronary artery disease,age >65+diabete mellitus)]]></trc:inclusionCriteria>    <trc:exclusionReason><![CDATA[]]></trc:exclusionReason>    <trc:N1>1704</trc:N1>    <trc:N0>1703</trc:N0>    <trc:design>Parallel groups</trc:design>    <trc:inclusionPeriod>aug 2000-sept 2001</trc:inclusionPeriod>    <trc:blindness>Open</trc:blindness>    <trc:FUduration>17.4 months</trc:FUduration>    <trc:lostFU>4.1%</trc:lostFU>    <trc:comment></trc:comment>    <trc:primaryEndpoint>All stroke or systemic embolism</trc:primaryEndpoint><trc:demonstratedBenefit>yes</trc:demonstratedBenefit>    <trc:jadad>5</trc:jadad>    <trc:centre>259</trc:centre>    <trc:area>europe,asia,australasia</trc:area>    <trc:remarkTreatment><![CDATA[Aspirin was used concurrently for at least half the period on study drug by 13% patients assigned to ximelagatran and 10% on warfarin(p=0.01).]]></trc:remarkTreatment>    <trc:remarkPatient><![CDATA[]]></trc:remarkPatient>    <trc:remarkMethod><![CDATA[Premature termination of study treatment was the result of study endpoint (4% warfarin group,3% ximelegatran) and adverse effects(4% warfarin group,8% ximelegatran group:this difference is related to elevation of liver enzymes in some patients treated with ximelegatran).
The trial was a non inferiority trial but the primary analysis was only by intention to treat.]]></trc:remarkMethod>    <trc:hypothesis></trc:hypothesis>    <trc:register></trc:register>    <trc:studyType>3</trc:studyType>    <trc:question>atrial fibrillation antithrombotics primary prevention of thromboembolic events</trc:question>    <trc:question>atrial fibrillation direct antithrombins all type of patients</trc:question>    <trc:question>atrial fibrillation new oral anticoagulants all type of patients</trc:question>    <trc:question>NMA Bayer new oral anticoagulants all types of patients</trc:question>    <trc:question>NMA BMS apixaban Afib new oral anticoagulants ARISTOFLE</trc:question>    <trc:question>NMA Bayer new oral anticoagulants rivaroxaban vs dabigatran</trc:question>    <trc:pathology>atrial fibrillation</trc:pathology>    <trc:pathology>NMA Bayer</trc:pathology>    <trc:pathology>NMA BMS apixaban Afib</trc:pathology>    <trc:mecanism>antithrombotics</trc:mecanism>    <trc:mecanism>direct antithrombins</trc:mecanism>    <trc:mecanism>new oral anticoagulants</trc:mecanism>    <trc:patient>primary prevention of thromboembolic events</trc:patient>    <trc:patient>All type of patient</trc:patient>